|
Feb 21
|
Hologic pockets CE mark for contrast biopsy software
|
|
Feb 21
|
Do Options Traders Know Something About Hologic (HOLX) Stock We Don't?
|
|
Feb 20
|
BD business separation could allow competitors to rise in IVD test markets
|
|
Feb 20
|
Hologic Obtains CE Mark for Affirm® Contrast Biopsy Software
|
|
Feb 19
|
FDA clears Hologic’s Aptima SARS-CoV-2 assay
|
|
Feb 18
|
Hologic Announces FDA Clearance of Aptima SARS-CoV-2 Assay
|
|
Feb 13
|
HOLX's New Offerings Likely to Revive Stock Amid Macro Woes
|
|
Feb 12
|
GE HealthCare Earnings: What To Look For From GEHC
|
|
Feb 11
|
Deciphering Hologic (HOLX) International Revenue Trends
|
|
Feb 11
|
QuidelOrtho Earnings: What To Look For From QDEL
|
|
Jan 3
|
Hologic price target lowered to $76 from $81 at Evercore ISI
|
|
Jan 2
|
Here's Why You Should Retain HOLX Stock in Your Portfolio Now
|
|
Nov 14
|
Hologic to Webcast Presentations at Upcoming Investor Conferences
|
|
Nov 8
|
Implied Volatility Surging for Hologic (HOLX) Stock Options
|
|
Nov 8
|
Hologic Post Q4 Earnings Miss: Time to Buy, Hold or Sell the Stock?
|
|
Sep 30
|
Hologic Unveils #BustTheMyth Campaign to Debunk Breast Cancer Myths and Empower Women This Breast Cancer Awareness Month
|
|
Sep 27
|
HOLX Stock Gains From New Offerings Despite Macro Issues
|
|
Sep 27
|
Is HOLX Stock a Smart Hold for Your Portfolio Right Now?
|
|
Sep 26
|
Hologic (HOLX) Gains But Lags Market: What You Should Know
|
|
Sep 25
|
Those who invested in Hologic (NASDAQ:HOLX) five years ago are up 67%
|